Table 4.
Comparison between patients with coexistent bullous pemphigoid and melanoma relative to the remaining patients with bullous pemphigoid
| BP with melanoma (n = 85) | BP without melanoma (n = 3839) | P value | |
|---|---|---|---|
| Age at the onset of BP, years; mean (SD) | 80.4 (10.2) | 76.6 (14.4) | 0.001 |
| Male sex, n (%) | 44 (51.8%) | 1623 (42.3%) | 0.079 |
| Jewish ethnicity, n (%) | 84 (98.8%) | 3668 (95.5%) | 0.144 |
| Body mass index; kg/m2, mean (SD) | 25.8 (3.5) | 27.9 (6.1) | < 0.001 |
| Smoking, n (%) | 26 (30.6%) | 1122 (29.2%) | 0.779 |
| Charlson comorbidity Index (w/o malignancies); mean (SD) | 2.7 (1.8) | 2.9 (2.2) | 0.413 |
| Long-term systemic corticosteroids, n (%)a | 58 (68.2%) | 2494 (65.0%) | 0.540 |
| Long-term topical corticosteroids, n (%)b | 83 (97.6%) | 3609 (94.0%) | 0.164 |
| Adjuvant immunosuppressant or immunomodulatory agentsc | 54 (63.5%) | 2283 (59.5%) | 0.457 |
| DPP4i-associated BP, n (%) | 5 (5.9%) | 291 (7.6%) | 0.558 |
| PD-1/PDL-1 antagonists-associated BP, n (%) | 1 (1.2%) | 5 (0.1%) | 0.004 |
n number, SD standard deviation, w/o without, DPP4i dipeptidyl peptidase-4 inhibitor, PD programmed death, PDL programmed death ligand
Bold: significant values
aPatients managed by systemic corticosteroids for more than 6 months
bPatients managed by topical corticosteroids for more than 6 months
cPatients managed by one of the following agents: azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide, dapsone, doxycycline, rituximab, plasmapheresis, intravenous immunoglobulins